

09 October 2023

Drugs used to treat Haemophilia

Under the Freedom of Information (FOI) Act 2000 I would like to obtain the following information:

1. In the last 3 months (July, August, and September 2023), how many Haemophilia A, Haemophilia B and von Willebrand patients were treated in your trust with the following coagulation factors:

- a. Hemlibra (non-inhibitor patients)
- b. Hemlibra (inhibitor patients)
- c. Advate
- d. Adynovi
- e. Elocta
- f. Esperoct
- g. NovoEight
- h. ReFacto AF
- i. Nuwiq
- j. Idelvion
- k. Refixia
- l. Alprolix
- m. BeneFIX
- n. Replenine
- o. Rixubis
- p. Voncento
- q. Veyvondi
- r. Wilate
- s. Willfact
- t. Alphanate
- u. Octanate
- v. Optivate
- w. Fahndi
- x. Haemate

2. In the last 3 months (July, August, and September 2023), how much volume in IU or mg was used of the following coagulation factors:

- a. Hemlibra (non-inhibitor patients)
- b. Hemlibra (inhibitor patients)
- c. Advate
- d. Adynovi
- e. Elocta
- f. Esperoct
- g. NovoEight

09 October 2023

- h. ReFacto AF
- i. Nuwiq
- j. Idelvion
- k. Refixia
- l. Alprolix
- m. BeneFIX
- n. Replenine
- o. Rixubis
- p. Voncento
- q. Veyvondi
- r. Wilate
- s. Willfact
- t. Alphanate
- u. Octanate
- v. Optivate
- w. Fahndi
- x. Haemate

3. In the last 3 months (July, August, and September 2023), how many patients switched from one of the following products to any other brand? Please indicate the brand that was switched to (i.e. Advate: 2 switches to Hemlibra, 3 switches to Elocta)

- a. Hemlibra (non-inhibitor patients)
- b. Hemlibra (inhibitor patients)
- c. Advate
- d. Adynovi
- e. Elocta
- f. Esperoct
- g. NovoEight
- h. ReFacto AF
- i. Nuwiq
- j. Idelvion
- k. Refixia
- l. Alprolix
- m. BeneFIX
- n. Replenine
- o. Rixubis
- p. Voncento
- q. Veyvondi
- r. Wilate
- s. Willfact
- t. Alphanate
- u. Octanate
- v. Optivate
- w. Fahndi
- x. Haemate

09 October 2023

The information requested is exempt under Section 21: Information already reasonably accessible. The information requested is readily available from the National Haemophilia Database (NHD).

We supply treatment in line with the National Framework and report all diagnosis, treatments and regimes on a quarterly basis to the National Haemophilia Database provided by the UKHCDO. Any individual/company can apply to the National Haemophilia Database for this information.